ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 208. FlatherMD,ShibataMC,CoatAJ,VanVeldhuisenDJ,ParkhomenkoA,Borbola J, et al; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-25. 209. Cadrin-Tourigny J, Shohoudi A, Roy D, Talajic M, Tadros R, Mondésert B, et al. Decreasedmortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation. JACC Heart Fail. 2017;5(2):99-106. 210. Pitt B, Zannad F, RemmeWJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone onmorbidity andmortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. 211. Zannad F, McMurray JJ, KrumH, van VeldhuisenDJ, Swedberg K, Shi H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. 212. Krum H, Shi H, Pitt B, McMurray J, Swedberg K, van Veldhuisen DJ, et al. Clinicalbenefitofeplerenoneinpatientswithmildsymptomsofsystolicheart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. CircHeart Fail. 2013;6(4):711-8. 213. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. 214. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin- angiotensin system inhibition for the treatment of heart failure. JACCHeart Fail. 2014;2(6):663-70. 215. Braunwald E. The path to an angiotensin receptor antagonist- neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015;65(10):1029-41. 216. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356(9320):608-9. 217. Langenickel TH, Tsubouchi C, Ayalasomayajula S, Pal P, Valentin MA, Hinder M, et al. The effect of LCZ696 (sacubitril/valsartan) on amyloid- β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol. 2016;81(5):878-90. 218. Oliva F, Sormani P, Contri R, Campana C, Carubelli V, Cirò A, et al. Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure. Int J Cardiol. 2018 Feb 15;253:97-104. 219. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85. 220. Anantha Narayanan M, Reddy YN, Baskaran J, Deshmukh A, Benditt DG, Raveendran G. Ivabradine in the treatment of systolic heart failure: a systematic review andmeta-analysis.World J Cardiol. 2017;9(2):182-90. 221. Tavazzi L, Swedberg K, Komajda M, BöhmM, Borer JS, Lainscak M, et al; SHIFT Investigators. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol. 2013;170(2):182-8. 222. BöhmM, Lloyd SM, Ford I, Borer JS, Ewen S, Laufs U, et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. Eur J Heart Fail. 2016;18(6):672-83. 223. Cleland JG, RobertsonM, Ford I, Mareev Y, Borer J, KomajdaM, et al. Effect of ivabradine onmortality in patients with heart failure and a reduced left ventricular ejection fraction not receivinga β -blocker: an analysis from SHIFT Investigators. Eur Heart J. 2017;38 (Suppl 1):A246. 224. Bocchi EA, Rassi S, Guimarães GV; Argentina, Chile, and Brazil SHIFT Investigators. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. ESC Heart Fail. 2018;5(3):249-56. 225. Komajda M, Tavazzi L, Swedberg K, Böhm M, Borer JS, Moyne A, et al; SHIFT Investigators. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur J Heart Fail. 2016;18(9):1182-9. 226. Turley SL, Francis KE, Lowe DK, Cahoon WD Jr. Emerging role of ivabradine for rate control in atrial fibrillation. Ther Adv Cardiovasc Dis. 2016;10(6):348-52. 227. Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of ivabradine. J Am Coll Cardiol. 2017;70(14):1777-84. 228. Bocchi EA, BohmM, Borer JS, Ford I, KomajdaM, Swedberg K, et al; SHIFT investigators.Effectofcombining ivabradineandbeta-blockers:focusonthe use of carvedilol in the shift population. Cardiology. 2015;131(4):218-24. 229. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity inpatientswithheart failure.NEnglJMed.1997;336(8):525-33. 230. Packer M. Does digitalis work in chronic heart failure? The end of a 200-year-old controversy. Cardiovasc Drugs Ther. 1989;2(6):743-6. 231. Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ. Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database Syst Rev. 2014 Apr 28;(4):CD002901. 232. Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.PLoS One. 2018;13(3):e0193924. 233. Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, et al; ARISTOTLE Committees and Investigators. Digoxin andmortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71(10):1063-74. 234. Felker GM, Lee KL, Bull DA, RedfieldMM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. 235. Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SE. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentrationinchronicheartfailure.JAmCollCardiol.2011;58(4):375-82. 236. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97(12):1759-64. 237. Dormans TP, Gerlag PG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J. 1996;17(12):1867-74 238. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, HarstonWE, Tristani FE, et al. Effect of vasodilator therapy onmortality in chronic congestive heart failure (results of a Veterans Administration Cooperative Study) . N Engl J Med. 1986;314(24):1547-52. 239. Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure (hemodynamic equivalency to sodium nitroprusside). Chest. 1978;73(1):8-13. 240. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5(3):178-87. 241. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049-57. 242. Mullens W, Abrahams Z, Francis GS, Sokos G, Starling RC, Young JB, et al. Usefulness of isosorbide dinitrate and hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol. 2009;103(8):1113-9. 243. Shah SJ, Katz DH, Deo RC. Phenotypic spectrum of heart failure with preserved ejection fracion. Heart Fail Clin. 2014;10(3):407-18. 244. Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: controversieschallengesandfuturedirections.Heart.2018;104(5):377-384. 245. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998–1005. 523